Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Conference Call March 12, 2022 4:30 PM ET
Company Participants
Jenny Kobin - IR
George Lasezkay - CEO
Charlie Deignan - CFO
Conference Call Participants
Annabel Samimy - Stifel
Operator
Greetings, and welcome to the Clearside Biomedical Q4 2023 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded.
I will now turn the conference over to your host, Jenny Kobin of Clearside Investor Relations. Jenny, you may begin.
Jenny Kobin
Good afternoon, everyone, and thank you for joining us on the call today. Before we begin, I would like to remind you that during today's call, we will be making certain forward-looking statements. Various remarks that we make during this call about the Company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our annual report on Form 10-K for the year ended December 31, 2023, that will be filed today, and our other SEC filings available on our website. In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.
On today's call, we have George Lasezkay, our Chief Executive Officer; and Charlie Deignan, our Chief Financial Officer. After our formal remarks, we will open the call for your questions.
I would now like to turn the call over to George.
George Lasezkay
Thank you, Jenny, and good afternoon, everyone. The tremendous progress that we accomplished in 2023 has propelled us into 2024 and positioned us for an important year. Last year, we advanced our CLS-AX clinical development program in wet AMD, meeting our targeted time line and budget. In February 2023, we reported positive results from our OASIS extension study that supported initiation of our Phase IIb clinical trial ODYSSEY.
Later that year, we initiated and completed enrolment in ODYSSEY again, on our targeted time line and budget. This rapid enrolment was primarily a result of significant enthusiasm from physicians because of the compelling aspects and potential clinical impact of the program.